In patients with FGFR3-altered urothelial carcinoma, erdafitinib achieved an objective response rate (ORR) of 40%, markedly outperforming chemotherapy, which yielded an ORR of 13% [5,223]. Here, FGFR3 is linked to urothelial carcinoma.